PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31910346-0	2020	Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies.	Yttrium-90	17-27	CEA cell adhesion molecule 3	Homo sapiens	50-74	
31910346-0	2020	Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies.	Yttrium-90	17-27	CEA cell adhesion molecule 3	Homo sapiens	120-144	
18256832-7	2008	A single dose of Y-90-labeled anti-CEA mAb, in combination with vaccine therapy, resulted in a statistically significant increase in survival in tumor-bearing mice over vaccine or mAb alone; this was shown to be mediated by engagement of the Fas/Fas ligand pathway.	Yttrium-90	17-21	CEA cell adhesion molecule 3	Homo sapiens	35-38	
19351765-0	2009	A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.	Yttrium-90	36-46	CEA cell adhesion molecule 3	Homo sapiens	55-84	
19351765-0	2009	A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.	Yttrium-90	36-46	CEA cell adhesion molecule 3	Homo sapiens	86-89	
19351765-0	2009	A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.	Yttrium-90	36-46	CEA cell adhesion molecule 3	Homo sapiens	133-136	
19351765-1	2009	PURPOSE: To determine the maximum tolerated dose of combined therapy using an yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody with gemcitabine in patients with advanced CEA-producing solid tumors.	Yttrium-90	78-88	CEA cell adhesion molecule 3	Homo sapiens	97-126	
19351765-1	2009	PURPOSE: To determine the maximum tolerated dose of combined therapy using an yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody with gemcitabine in patients with advanced CEA-producing solid tumors.	Yttrium-90	78-88	CEA cell adhesion molecule 3	Homo sapiens	128-131	
19351765-1	2009	PURPOSE: To determine the maximum tolerated dose of combined therapy using an yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody with gemcitabine in patients with advanced CEA-producing solid tumors.	Yttrium-90	78-88	CEA cell adhesion molecule 3	Homo sapiens	185-188	
19351765-14	2009	CONCLUSIONS: Feasibility of combining gemcitabine with an yttrium-90-labeled anti-CEA antibody is shown with preliminary evidence of clinical response.	Yttrium-90	58-68	CEA cell adhesion molecule 3	Homo sapiens	82-85	
3675197-0	1987	Therapy of peritoneal carcinomatosis of human colon cancer xenografts with yttrium 90-labeled anti-carcinoembryonic antigen antibody ZCE025.	Yttrium-90	75-85	CEA cell adhesion molecule 3	Homo sapiens	94-123	
11051230-0	2000	A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.	Yttrium-90	46-55	CEA cell adhesion molecule 3	Homo sapiens	69-93	
11051230-0	2000	A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.	Yttrium-90	46-55	CEA cell adhesion molecule 3	Homo sapiens	95-98	
11051230-0	2000	A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.	Yttrium-90	46-55	CEA cell adhesion molecule 3	Homo sapiens	144-147	
8436526-2	1993	Radioimmunotherapy was delivered by intraperitoneal injection of 90Y-labeled anticarcinoembryonic antigen monoclonal antibody (anti-CEA MAB).	Yttrium-90	65-68	CEA cell adhesion molecule 3	Homo sapiens	132-135